95bFM

Oto and Jaycee played a bunch of new releases by artists from Southeast-Asia, Asia and beyond.

Pharmac has announced its decision to fund the drug, Enhertu, used for slowing the advancement of the HER2-positive form of breast cancer, beginning on the 1st of January, 2025. Alongside this funding, two eligibility restrictions will be removed.

HER2-positive breast cancer is an aggressive form of breast cancer, where the human epidermal growth factor receptor 2 protein is present, and encourages the growth of cancer cells.

Producer Athena spoke to Chief Executive at the Breast Cancer Foundation New Zealand, Ah-Leen Rayner, about how Enhertu compares to other breast cancer medicines, the removal of eligibility restrictions, and how the Breast Cancer Foundation pushed for this change.

This past week has seen the reign of Syrian President Bashar Al-Assad collapse, his rule toppled by a group of United States backed rebels. The vacuum left by his absence is expected to be felt by those within and outside of Syria. 

To help explain the geopolitical impacts of the fall of the Assad regime, Wire host Castor spoke to Associate Professor Stephen Hoadley.

This week I was mostly listening to...

Keeping it chill i tēnei ata x

Playlist here, but if you like a track / artist listen on bandcamp / otherwise if you can :) 

Ngā mihi nui to The Tuning Fork !

This week on Dear Science, our expert Doctor Cushla McGoverin chatted with us about what latrines teach us about people, climate variation affecting Chinese dynasties, and invasive species becoming threatened.

Thanks to MOTAT, the museum inspiring the innovators of tomorrow!

Jonny catches up with Deputy Mayor Desley Simpson about a new council policy that limits alcohol licensing so that  liquor retailers now must stop selling by 9PM. The policy will be running for 12 months as a trial, and also places a two-year freeze on opening new off-license retailers in 23 suburbs. Read more about it here

Pharmac recently announced its decision to bring back funding for the respiratory medicine, palivizumab, beginning on the 1st of January, 2025. Palivizumab is used to prevent respiratory syncytial virus (RSV) in children and babies, but went unfunded for a year after October of 2023. 

Alongside the new palivizumab funding announcement, Pharmac also announced funding for a new triple inhaler for people with chronic obstructive pulmonary disease (COPD).

Producer Athena spoke to University of Otago Professor, and Medical Director at the Asthma and Respiratory Foundation New Zealand, Bob Hancox, about the effectiveness of palivizumab, the benefits of the new triple inhaler, and what these funding announcements mean for Kiwis with respiratory issues.

Featuring Isthmus'n That with Deputy Mayor Desley Simpson and Short Player thanks to NZOA Music - ICYMI on Rāhoroi, Hunter chatted to Mokotron about his new album WAEREA. Also an exciting announce that 95bFM is pleased to present Fazerdaze playing her sophmore album Soft Power at the Powerstation next year!

For Dear Science this week, our expert Doctor Cushla McGoverin chatted with us about what latrines teach us about people, climate variation affecting Chinese dynasties, and invasive species becoming threatened. 

In our weekly catchup with the National Party, Wire host Castor spoke to MP Tom Rutherford about the government’s police staffing targets and changes to national insulation standards. 

They also spoke to Associate Professor Steve Hoadley about the geopolitical consequences of the fall of the Assad regime in Syria. 

Producer Athena spoke to Medical Director at the Asthma and Respiratory Foundation New Zealand, and Professor at the University of Otago, Bob Hancox, about Pharmac’s decision to fund respiratory medicines: pali-vizu-mab, and a new triple inhaler.

And they spoke to the Breast Cancer Foundation New Zealand's Chief Executive, Ah-Leen Rayner about Pharmac’s decision to fund a new breast cancer drug, Enhertu